For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months ...

In a year of pivotal gastroenterology research, these 10 articles were in a class of their own, according to Dr David Johnson ...

For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months ...

Upadacitinib may offer superior disease management than tofacitinib for patients with ulcerative colitis. Learn more.

Managing inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, may soon become more advanced and ...

Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

Developed by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.

Early diagnosis is vital to ensure people get on the right treatment path as soon as possible. Until now, there was no single ...

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...

A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a UM ...

More than half (62.7%) of respondents reported facing financial barriers to obtaining their IBD medication.

Understanding current trends in the incidence, prevalence, and distribution of ulcerative colitis can help inform diagnosis and treatment.